{"title":"An update on topical therapies for psoriasis.","authors":"Emily K Pender, Brian Kirby","doi":"10.1097/BOR.0000000000001018","DOIUrl":null,"url":null,"abstract":"PURPOSE OF REVIEW\nTopical therapies are a mainstay of treatment for mild psoriasis and may be a useful adjunct in treatment of moderate-to-severe psoriasis. This review summarizes recent advances in topical therapies for psoriasis and currently available treatments.\n\n\nRECENT FINDINGS\nTopical aryl hydrocarbon receptor modulators (tapinarof) and topical phosphodiesterase-4 inhibitors (roflumilast) have been proven effective in randomized controlled trials for psoriasis. Although topical JAK inhibitors have also been studied, none are currently licensed for treatment of psoriasis. Topical corticosteroids and vitamin D analogues remain the most commonly used and widely available topical treatments for psoriasis. Cost may limit use of novel topical agents.\n\n\nSUMMARY\nAlthough the novel topical agents tapinarof and roflumilast are licensed for treatment of psoriasis by the FDA in the United States, they have not yet been licensed in Europe, and it remains to be seen whether they will be limited by cost.","PeriodicalId":5,"journal":{"name":"ACS Applied Materials & Interfaces","volume":"58 42","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Materials & Interfaces","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BOR.0000000000001018","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
PURPOSE OF REVIEW
Topical therapies are a mainstay of treatment for mild psoriasis and may be a useful adjunct in treatment of moderate-to-severe psoriasis. This review summarizes recent advances in topical therapies for psoriasis and currently available treatments.
RECENT FINDINGS
Topical aryl hydrocarbon receptor modulators (tapinarof) and topical phosphodiesterase-4 inhibitors (roflumilast) have been proven effective in randomized controlled trials for psoriasis. Although topical JAK inhibitors have also been studied, none are currently licensed for treatment of psoriasis. Topical corticosteroids and vitamin D analogues remain the most commonly used and widely available topical treatments for psoriasis. Cost may limit use of novel topical agents.
SUMMARY
Although the novel topical agents tapinarof and roflumilast are licensed for treatment of psoriasis by the FDA in the United States, they have not yet been licensed in Europe, and it remains to be seen whether they will be limited by cost.
综述目的局部疗法是治疗轻度银屑病的主要方法，也可能是治疗中重度银屑病的有效辅助疗法。本综述总结了银屑病局部疗法的最新进展以及目前可用的治疗方法。最新发现局部芳基烃受体调节剂（tapinarof）和局部磷酸二酯酶-4抑制剂（roflumilast）已在银屑病随机对照试验中被证实有效。虽然也对外用 JAK 抑制剂进行了研究，但目前还没有任何一种抑制剂被许可用于治疗银屑病。外用皮质类固醇激素和维生素 D 类似物仍然是最常用、最广泛的银屑病外用疗法。总结虽然新型外用药物他匹那罗夫和罗氟司特已获得美国 FDA 批准用于治疗银屑病，但它们尚未在欧洲获得许可，而且它们是否会受到成本的限制还有待观察。
期刊介绍：
ACS Applied Materials & Interfaces is a leading interdisciplinary journal that brings together chemists, engineers, physicists, and biologists to explore the development and utilization of newly-discovered materials and interfacial processes for specific applications. Our journal has experienced remarkable growth since its establishment in 2009, both in terms of the number of articles published and the impact of the research showcased. We are proud to foster a truly global community, with the majority of published articles originating from outside the United States, reflecting the rapid growth of applied research worldwide.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
